Holen Sie sich die Stockscreener-App
7.58
6.77%
-0.55
Handel nachbörslich:
7.68
0.10
+1.32%
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Scienture Holdings, Inc. to Participate in The Microcap Conference 2025 - Nasdaq
Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025 - GlobeNewswire
Scienture Holdings to Present at Microcap Conference 2025: Strategic Growth Plans in Focus - StockTitan
Trxade Group, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019 - Marketscreener.com
Trxade Group, Inc. acquired Community Specialty Pharmacy, LLC from Nikul Panchal for $0.6 million. - Marketscreener.com
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041 - GlobeNewswire
Scienture Secures Crucial Patent Protection for Novel Losartan Oral Suspension Through 2041 - StockTitan
Scienture Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Scienture announces private placement of $3M of 10% secured convertible debentures - MSN
Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement - The Manila Times
Scienture Holdings Secures Funding for Strategic Growth - TipRanks
Scienture Holdings Secures $62M in Strategic Financing, Including $12.2M Debenture Deal | SCNX Stock News - StockTitan
Walgreens Boots Alliance (WBA) Stock Surges Amid Market Activity - GuruFocus.com
Scienture Holdings: Q3 Earnings Snapshot - CTPost
White Mountains: Q3 Earnings Snapshot - AOL
Scienture completes preferred stock conversion By Investing.com - Investing.com Australia
Scienture completes preferred stock conversion - Investing.com India
Scienture : Material Event Form 8 K - Marketscreener.com
Scienture Holdings Shares Insight with Investor Presentation - TipRanks
Gajan A. Mahendiran and Amudha Mahendiran acquired Westminster Pharmaceutical LLC from Trxade Group, Inc. for $1.6 million. - Marketscreener.com
Top Premarket Gainers - Marketscreener.com
Scienture Holdings Unveils New Identity Post-Merger - TipRanks
TRxADE Health changes its name to Scienture Holdings - AlphaStreet
Bats Reveal Superior Adaptation to Endure Heart Stress: National Heart Centre Singapore Partners Paratus Sciences Singapore to Accelerate Heart Failure Care - ForexTV.com
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner - ForexTV.com
TRxADE Health rebrands as Scienture Holdings with new ticker SCNX - Investing.com
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX” - Morningstar
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. - ForexTV.com
Trxade Health announces name change to Scienture Holdings - TipRanks
Guardian Pharmacy seeks to raise up to $108 mil in US IPO - AlphaStreet
Everything you need to know about Zenas BioPharma’s IPO - AlphaStreet
Trxade Group’s Strategic Merger and Rebranding as Scienture Holdings - TipRanks
TRxADE HEALTH completes all-stock merger deal with Scienture - World Pharmaceutical Frontiers
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million - StockTitan
Envoy Medical is well-positioned to gain market share in hearing implant space: CEO - AlphaStreet
AgEagle’s latest focus is on tailoring products for defense, public safety industries: CEO - AlphaStreet
TRxADE Health, Inc. Announces Special Cash Dividend | MEDS Stock News - StockTitan
Everything you need to know about OS Therapies’ upcoming IPO - AlphaStreet
MEDS Earnings: Highlights of Trxade Health’s Q1 2024 financial results - AlphaStreet
TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale - StockTitan
Alumis looks to raise $300 million in IPO. Here’s what you need to know - AlphaStreet
Tempus AI gears up for IPO. Here’s everything you need to know - AlphaStreet
Trxade Health Inc. (NASDAQ: MEDS) Q1 2024 Research Summary - AlphaStreet
Femasys is committed to providing women with revolutionary healthcare products: CEO - AlphaStreet
Trxade Health, Inc. Announces Special Cash Dividend, Payable on or About March 22, 2024 - Marketscreener.com
Trxade Health Inc. (NASDAQ: MEDS) Q4 2023 Research Summary - AlphaStreet
MEDS Earnings: A snapshot of Trxade Health’s Q3 2023 financial results - AlphaStreet
TRxADE: Q3 Earnings Snapshot - Marketscreener.com
Nordic Group makes another acquisition to diversify earnings base - Yahoo Finance
Trxade Health Inc. (NASDAQ: MEDS) Q3 2023 Research Summary - AlphaStreet
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor - AlphaStreet
symbol__ Stock Quote Price and Forecast - CNN
Continued focus on core B2B segment drives new business: Trxade CEO Suren Ajjarapu - AlphaStreet
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel - AlphaStreet
Earnings: Trxade Health (MEDS) reports 16% rise in FY22 revenue; loss narrows - AlphaStreet
TRxADE HEALTH, Inc. Announces Janet Huffman, the Chief Financial Officer Terminate Her Offer Letter and Transitioned from Chief Financial Officer to Acting Chief Financial Officer - Marketscreener.com
Current initiatives should enable Flux Power to reach profitability: CEO Ron Dutt - AlphaStreet
Trxade Health Inc. (NASDAQ: MEDS) Q4 2022 Research Summary - AlphaStreet
Block Inc (SQ-N) QuotePress Release - The Globe and Mail
Trxade (MEDS) is increasing the breadth of product offerings: CEO Suren Ajjarapu - AlphaStreet
Trxade CEO Suren Ajjarapu: Will see the impact of GPO program by Q3 next year - AlphaStreet
2.55%
2.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):